<DOC>
	<DOCNO>NCT01065558</DOCNO>
	<brief_summary>The purpose study determine effect ecopipam patient Lesch-Nyhan Disease ( LND ) . Ecopipam specifically block action one chemical brain help nerve talk one another ; ecopipam stop chemical ( dopamine ) bind one family receptor ( i.e , D1 family ) . LND rare genetic disease . The sponsor study find side effect ecopipam cause LND patient , whether ecopipam may able relieve self-injurious behavior see patient .</brief_summary>
	<brief_title>Safety Tolerability D1 Dopamine Receptor Antagonist Ecopipam Patients With Lesch-Nyhan Disease</brief_title>
	<detailed_description />
	<mesh_term>Self-Injurious Behavior</mesh_term>
	<mesh_term>Lesch-Nyhan Syndrome</mesh_term>
	<mesh_term>Ecopipam</mesh_term>
	<mesh_term>Dopamine Antagonists</mesh_term>
	<criteria>Inclusion Criteria Diagnosis LeschNyhan disease moderate severe Self Injurious Behavior routinely restrain Male 6 year age Body weight great equal 44 pound Taking Neuroleptic Dopamine Depleting medication Currently treat medication depression seizure Impaired renal function Medical condition may interfere complete study</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ecopipam</keyword>
	<keyword>Lesch-Nyhan Disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Self-Injurious Behavior</keyword>
</DOC>